Breast Cancer Risk Biomarkers in Premenopausal Women
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Carol Fabian, MD, University of Kansas Medical Center Research Institute
First received: November 23, 2010
Last updated: September 23, 2012
Last verified: September 2012
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
||Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids
Primary Outcome Measures:
Secondary Outcome Measures:
- To assess the potential efficacy as demonstrated by significant modulation of one or more risk biomarkers [ Time Frame: 6 month visit ] [ Designated as safety issue: No ]
To assess the potential efficacy as demonstrated by significant modulation of one or more risk biomarkers.
- To assess change in cell fatty acid signatures with Lovaza™ [ Time Frame: 6 month visit ] [ Designated as safety issue: No ]
To assess change in cell fatty acid signatures with Lovaza™ especially change in erythrocyte and breast tissue phospholipid EPA and DHA or the combination relative to Arachidonic Acid (AA), or omega-3: omega 6, and correlate these changes with those in risk biomarkers, mechanism of action biomarkers, and total oral intake.
- To measure change in quality of life with Lovaza™ [ Time Frame: 6 month visit ] [ Designated as safety issue: No ]
To measure change in quality of life with Lovaza™ and correlate with change with change in erythrocyte phospholipid fatty acid signatures, particularly EPA:AA, DHA:AA, EPA +DHA:AA
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||November 2013 (Final data collection date for primary outcome measure)
4 capsules daily for 6 months
|Ages Eligible for Study:
||25 Years to 54 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Subjects must be premenopausal and between the ages of 25 and 54 and must have had a menstrual period within the past 12 months. Women who are not menstruating regularly due to use of certain types of contraceptives may be entered with restrictions. Their estrogen progesterone, and FSH levels must be documented at baseline RPFNA and their off study RPFNA must take place at a similar portion of their cycle (high or low progesterone levels). In order to do this a serum progesterone will have to be obtained ~ 4 weeks before planned RPFNA and again 2 weeks later such that the RPFNA can be performed in the same phase of the "cycle" as baseline.
- Subjects must be at increased risk for breast cancer on the basis of at least one of the following criteria:
- A five-year Gail risk of ≥ 1.67% or 3X the average risk for a woman of the same age using either the Surveillance Epidemiology and End Results (SEER, http://seer.cancer.gov) database or the NCI Breast Cancer Risk Assessment Tool (www.cancer.gov/bcrisktool)., or 10 yr Tyrer-Cuzick risk 2x population risk as listed in model, or RPFNA atypia
- BMI <40 Kg/m3
- A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer.
- Multiple prior biopsies or at least one prior biopsy exhibiting atypical hyperplasia (AH), LCIS, DCIS.
- RPFNA evidence of hyperplasia with atypia within the last three years;
- Chest or neck radiation before age 30;
- Mammographic breast density by visual estimate equals or exceeds 50%.
- Subjects must be willing to continue the same hormonal milieu present at baseline throughout trial. If not using an oral, vaginal, or topical contraceptive, must be willing to actively use barrier methods of contraception to prevent pregnancy.
- Six months or more must have elapsed from completion of a prevention intervention trial (with exception of a weight reduction trial), ingestion of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) prior to baseline biomarker assessment.
- Subjects must be willing to undergo measurement of height, weight, and BMI and undergo body composite analysis (DEXA) at initiation and conclusion of intervention.
- Subjects with a history of AH, LCIS, or ER-positive DCIS by diagnostic biopsy, must have been counseled about appropriate standard prevention therapies such as tamoxifen and are either not eligible or are not interested in standard prevention therapies. Women with DCIS must have had appropriate local therapy (lumpectomy plus radiation or mastectomy). If subject has had a DCIS, at least two months must have elapsed from surgery and/or radiation therapy to the involved breast. Only the contralateral (uninvolved breast) will be studied by RPFNA. The subject may not have had any radiation therapy to the contralateral breast to be studied
- Subjects > 40 must have had a screening mammogram within 6 months of entering the interventional portion of the study and read as not suspicious for breast cancer or if suspicious must have completed all suggested tests including biopsy and found to have no evidence of cancer. Subjects of sufficient age and/or risk for a baseline mammogram must be willing to have an off-study mammogram performed 6 months after study entry.
- Subjects must have had an RPFNA of the breast within six months prior to entering the intervention portion of the study and be willing to have another RPFNA at ~6.5 months after starting Lovaza™.
- Tissue Eligibility: Subjects must have cytomorphologic evidence of hyperplasia with atypia or borderline atypia (Masood score 14 or higher). There must be ≥500 epithelial cells on the slide for cytomorphology and evidence of proliferation by Ki-67 staining. There must be sufficient reserved methanol- formalin-fixed material for RT-qPCR. Frozen tissue must also have been obtained for fatty acid analysis, reverse phase proteomics, adipokines and cytokines, and RT-qPCR.
- Subjects must be willing to undergo phlebotomy at baseline, and 6 months and 6.5 months approximately 3 tablespoons of blood will be obtained at baseline, and 6 months and 6.5 months or 6 tablespoons if the subject decides to participate in the optional monocyte cytokine release assay .
- Subjects must produce a spot urine sample at baseline, 6 months and at study conclusion. Baseline urine sample will in part be used to document that subject is not pregnant.
- Subjects must be willing to complete questionnaires regarding diet and supplement use, quality of life, relevant family history, personal health and reproductive history and medications at initiation and conclusion of the intervention.
- Subjects must be willing to sign an informed consent for the entire study and separate consent for repeat RPFNA
- Women that have had a metastatic malignancy of any kind.
- Women that have had prior invasive breast cancer, diagnosed or treated within the past five years.
- Women who are currently taking anticoagulants.
- Women who have breast implants.
- Women who have undergone change in their hormonal milieu in the past 6 months this includes pregnancy, lactation, or stopping or starting hormonal contraceptives..
- Women who have taken omega 3 fatty acid supplements within 3 weeks prior to their baseline RPFNA.
- Women who regularly take NSAIDS (>7 tablets weekly).
Inclusion of Women and Minorities
-This study utilizes women at increased risk for breast cancer. Subjects recruited from an established cohort of women followed in the Breast Cancer Prevention Center. From previous trials we can expect 6% minority accrual which is similar to our hospital demographics. Males are not included due to the low absolute risk of breast cancer, and the difficulty of performing RPFNA on the male breast.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01252277
|University of Kansas Medical Center
|Kansas City, Kansas, United States, 66160 |
Carol Fabian, MD
||Carol Fabian, MD
||University of Kansas
No publications provided
||Carol Fabian, MD, Professor, Director Breast Cancer Prevention Unit, University of Kansas Medical Center Research Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 23, 2010
||September 23, 2012
||United States: Human Subjects Committee
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 11, 2013
Neoplasms by Site